Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Visualization of beta-Adrenoceptors Using PET.

Philip H. Elsinga1, Aren van Waarde, Ton J. Visser

  • 1PET Center, Groningen University Hospital, Groningen, The Netherlands

Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T
|October 1, 2003
PubMed
Summary

Positron emission tomography (PET) imaging of beta-adrenoceptors is clinically relevant for heart, lung, and brain conditions. [(11)C]CGP 12388 shows promise as a PET ligand for studying cardiac and pulmonary beta-adrenoceptors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of the adenosine A<sub>2A</sub> receptor antagonist KW6002 on the dopaminergic system, motor performance, and neuroinflammation in a rat model of Parkinson's disease.

Neuropharmacology·2024
Same author

Pharmacokinetic Analysis of [<sup>18</sup>F]FES PET in the Human Brain and Pituitary Gland.

Molecular imaging and biology·2024
Same author

Characterization of a novel model for atherosclerosis imaging: the apolipoprotein E-deficient rat.

EJNMMI research·2023
Same author

Perinatal exposure to the immune-suppressant di-n-octyltin dichloride affects brain development in rats.

Toxicology mechanisms and methods·2023
Same author

Impact of an Adenosine A<sub>2A</sub> Receptor Agonist and Antagonist on Binding of the Dopamine D<sub>2</sub> Receptor Ligand [<sup>11</sup>C]raclopride in the Rodent Striatum.

Molecular pharmaceutics·2022
Same author

Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D<sub>2</sub> and Histamine H<sub>3</sub> Receptors: A PET Study in Healthy Rats.

Molecular pharmaceutics·2022

Area of Science:

  • Nuclear medicine
  • Pharmacology
  • Cardiology

Background:

  • Beta-adrenoceptors in the heart, lungs, and brain are clinically significant.
  • Receptor densities change with various pathophysiological conditions.
  • PET imaging offers in vivo insights into beta-adrenoceptor status.

Purpose of the Study:

  • To review PET research on beta-adrenoceptors.
  • To discuss the clinical relevance of PET investigations for beta-adrenoceptors in the heart, lungs, and brain.
  • To evaluate available PET ligands for beta-adrenoceptor imaging.

Main Methods:

  • Review of existing literature on PET ligands for beta-adrenoceptor imaging.
  • Discussion of results obtained with specific PET ligands, including [(11)C]CGP 12177, [(18)F]-fluorocarazolol, [(11)C]Carazolol, and [(11)C]CGP 12388.

Related Experiment Videos

  • Assessment of ligand properties such as lipophilicity, non-specific binding, toxicity, and ease of preparation.

    • Main Results:

    • [(11)C]CGP 12177 is useful in cardiac and pulmonary diseases but has a complex labeling procedure.
    • [(18)F]-fluorocarazolol is suitable for various sites but has high non-specific binding and toxicity concerns.
    • [(11)C]Carazolol has limited brain penetration.
    • [(11)C]CGP 12388 is easier to prepare than [(11)C]CGP 12177 and shows promise for clinical studies.
    • [(11)C]formoterol may allow investigation of the beta(2)-subtype high affinity state.

    Conclusions:

    • [(11)C]CGP 12388 is a promising PET ligand for clinical studies of cardiac and pulmonary beta-adrenoceptors due to its favorable pharmacokinetics and easier preparation.
    • Further research with ligands like [(11)C]formoterol could enable investigation of specific beta-adrenoceptor subtypes.